01—Abstract
Summary
Summary of the 10-Q filed April 23, 2025. Cited figures are marked; the original filing is the authoritative source.
Intuitive Surgical Inc. (ISRG) reported strong financial results for the first quarter of 2025, demonstrating robust top-line growth and continued expansion in its core robotic surgery business.
Total revenue increased by a significant 19% year-over-year to $2.25 billiona, driven by strong performance across all revenue segments, particularly in instruments and accessories, systems, and services. The company saw a substantial increase in da Vinci procedure volume, up 17%, alongside a notable 58% surge in Ion endoluminal procedures, indicating growing adoption of its minimally invasive solutions. Key financial metrics highlight the company's operational efficiency and continued investment in innovation.
Gross profit margin remained healthy at 64.7%, with operating income growing 23%. The company also reported a healthy cash position, ending the quarter with $9.10 billionb in cash, cash equivalents, and investments, providing ample liquidity for future growth initiatives, ongoing R&D, and potential strategic acquisitions. The increase in systems revenue and strong da Vinci 5 system placements signal positive market reception for newer generation products.
02—Key points
Key Highlights
- Total revenue grew 19% to $2.25 billion, driven by strong performance across all segments.
- Da Vinci procedures increased by 17%, indicating continued adoption of robotic surgery.
- Ion endoluminal procedures saw substantial growth of 58%, highlighting expansion beyond traditional surgery.
- Instruments and accessories revenue grew 18%, reflecting increased procedure volume.
- Systems revenue increased by 25%, boosted by higher da Vinci system placements, including 147 da Vinci 5 systems.
- Operating income rose 23%, demonstrating effective cost management and operational leverage.
- The company maintained a strong liquidity position with $9.10 billion in cash, cash equivalents, and investments.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q1 FY2025, Intuitive Surgical kept $0.31.
- Revenue$2.25B100.0%
- Cost of revenue−$795.7M35.3%
- Gross profit$1.46B64.7%
- Operating costs−$879.6M39.0%
- Operating income$578.1M25.7%
- Interest, other & tax$120.3M5.3%
- Net income$698.4M31.0%
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed April 23, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $2.25B$1.89B | +19.2% |
| Cost of Revenue | $795.70M$645.20M | +23.3% |
| Gross Profit | $1.46B$1.25B | +17.0% |
| R&D Expenses | $316.20M$284.50M | +11.1% |
| SG&A Expenses | $563.40M$491.50M | +14.6% |
| Operating Expenses | $879.60M$776.00M | +13.4% |
| Operating Income | $578.10M$469.40M | +23.2% |
| Net Income | $698.40M$544.90M | +28.2% |
| EPS (Basic) | $1.95$1.54 | +26.6% |
| EPS (Diluted) | $1.92$1.51 | +27.2% |
| Shares Outstanding (Basic) | 357.50M353.50M | +1.1% |
| Shares Outstanding (Diluted) | 364.60M360.50M | +1.1% |
05—Questions
Frequently Asked Questions
What were the primary drivers of revenue growth in Q1 2025?
Revenue growth was primarily driven by a 17% increase in da Vinci procedures and a 58% increase in Ion procedures. This led to an 18% increase in instruments and accessories revenue, a 25% increase in systems revenue, and a 16% increase in service revenue. The strong performance of the da Vinci 5 system placements also contributed significantly to the systems revenue growth.
How is the company managing potential impacts from global tariffs and macroeconomic uncertainties?
The company notes that while the impact of tariffs on its first quarter 2025 results was immaterial, it anticipates a significant increase in its cost of revenues in the second half of 2025 due to recently announced and implemented global tariffs. It is actively monitoring supply chain risks, inflationary pressures, and elevated interest rates, and is engaged in activities to mitigate their impact on operations. Specific concerns include tariffs on imports from China impacting da Vinci Xi surgical system costs and competitiveness in that region.
What is the outlook for new product introductions and adoption?
Intuitive Surgical is continuing to advance its product pipeline. The company reported FDA clearance for its SP SureForm 45 stapler and curved-tip stapler in March 2025 for use with the da Vinci SP surgical system. The phased launch of the next-generation da Vinci 5 system is progressing, with 147 units placed in Q1 2025. The Ion endoluminal system also continues to see strong procedural growth and installed base expansion.
What are the key risks and legal proceedings the company is currently facing?
The company faces ongoing product liability litigation related to the da Vinci surgical system. It is also involved in patent and commercial litigation, including antitrust claims related to the service and repair of its instruments. While the company is defending itself, it acknowledges that the ultimate outcome of these matters could have a material adverse effect on its business, financial condition, or future results of operations. The company cannot estimate a range of loss for certain legal matters.
06—Continue